Baxter International BAX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Healthcare Systems & Technologies | $3.07B0.0% | $3.07B+1.4% | $3.03B+0.7% | $3.01B+0.6% | $2.99B+1.3% | |
| Medical Products & Therapies | $5.32B+0.4% | $5.3B+1.4% | $5.23B-0.2% | $5.24B0.0% | $5.24B+0.6% | |
| Pharmaceuticals | $2.53B+1.6% | $2.49B+1.0% | $2.47B+1.8% | $2.42B+0.4% | $2.41B+0.1% | |
| Net Sales by Product | ||||||
| Advanced Surgery | $1.23B+3.0% | $1.2B+3.1% | $1.16B+3.0% | $1.13B+1.7% | $1.11B+0.5% | |
| Care & Connectivity Solutions | $1.92B+0.4% | $1.91B+1.8% | $1.88B+0.9% | $1.86B+1.2% | $1.84B+1.4% | |
| Drug Compounding | $1.22B+6.5% | $1.14B+5.2% | $1.09B+3.0% | $1.05B+1.8% | $1.03B-0.4% | |
| Front Line Care | $1.15B-0.6% | $1.16B+0.9% | $1.15B+0.3% | $1.15B-0.3% | $1.15B+1.1% | |
| Infusion Therapies & Technologies | $4.09B-0.3% | $4.1B+0.9% | $4.06B-1.1% | $4.11B-0.5% | $4.13B+0.7% | |
| Injectables & Anesthesia | $1.32B-2.5% | $1.35B-2.2% | $1.38B+0.9% | $1.37B-0.7% | $1.38B+0.5% | |
| Net Sales by Geography | ||||||
| International | $5.25B+2.6% | $5.12B+3.6% | $4.94B+1.9% | $4.85B+1.5% | $4.78B-0.1% | |
| United States | $6.07B-0.9% | $6.12B+0.7% | $6.08B+0.7% | $6.04B+0.7% | $5.99B+2.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Baxter International break its business down?
- Baxter International (BAX) reports net sales by business across 3 parts — Healthcare Systems & Technologies, Medical Products & Therapies and Pharmaceuticals. Each is extracted from the segment footnotes and tracked over time.
- Where does Baxter International's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Baxter International's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
